Related Experiment Video

Updated: Apr 1, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.0K

Genetic Polymorphisms of miR-146a and miR-155 in Psoriasis and Psoriatic Arthritis: Evidence from a Turkish

Fadime Mutlu Icduygu1, Isil Deniz Oguz2, Egemen Akgun3

  • 1Department of Medical Genetics, Faculty of Medicine, Giresun University, Giresun, Turkey.

Dermatology Practical & Conceptual
|March 30, 2026
PubMed
Abstract

Insights

Genetic variants in miR-155 and miR-146a are associated with psoriasis susceptibility in the Turkish population. These microRNA variants may influence disease onset and severity but not psoriatic arthritis development.

Area of Science:

  • Genetics
  • Immunology
  • Dermatology

Background:

  • Psoriasis is a common inflammatory skin condition influenced by genetic and environmental factors.
  • MicroRNAs (miRNAs), specifically miR-155 and miR-146a, play roles in regulating inflammatory processes.
  • Understanding the genetic basis of psoriasis susceptibility is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the association between specific genetic variants (rs767649 in miR-155 and rs2910164 in miR-146a) and the risk of developing psoriasis and psoriatic arthritis.
  • To explore the potential correlation of these variants with disease severity and age of onset in psoriasis patients.

Main Methods:

  • A case-control study involving 544 participants (284 psoriasis cases, 260 controls).
  • Genotyping of miR-155 rs767649 and miR-146a rs2910164 variants using real-time polymerase chain reaction (qPCR).
  • Statistical analysis to compare allele and genotype frequencies between patient and control groups, and to assess associations with clinical parameters.

Main Results:

  • The miR-146a rs2910164 C allele and associated genotypes (CC, GC) were more frequent in psoriasis patients (P<0.001).
  • The miR-155 rs767649 A allele and AA genotype were more prevalent in controls (P=0.005, P=0.002).
  • Rs2910164 polymorphism correlated with earlier disease onset (P=0.006) and higher Psoriasis Area and Severity Index (PASI) scores (P=0.024).

Conclusions:

  • The study suggests that miR-155 rs767649 and miR-146a rs2910164 variants are linked to psoriasis susceptibility in the Turkish population.
  • No significant association was found between these variants and the development of psoriatic arthritis.
  • The miR-146a rs2910164 variant is associated with earlier psoriasis onset and increased disease severity.

More Related Videos

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice09:13

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice

Published on: July 11, 2025

34.9K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K